Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 13Leukemia 8Recurrence 6Melanoma 5Leukemia, Myelomonocytic, Chronic 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Blast Crisis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Thrombocytopenia 1Skin Neoplasms 1Sarcoma, Synovial 1Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden 1Prostatic Neoplasms 1Peripheral Blood Stem Cell Transplantation 1Neuroectodermal Tumors, Primitive 1Myeloproliferative Disorders 1Myeloid Malignancies 1Mesothelioma, Malignant 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 91Carboplatin 73Pemetrexed 58Nivolumab 50Docetaxel 47Cisplatin 47Paclitaxel 46Erlotinib Hydrochloride 37Radiotherapy 30Gemcitabine 27osimertinib 23Cetuximab 23Bevacizumab 21Ipilimumab 18Radiosurgery 14130-nm albumin-bound paclitaxel 14Taxes 13Gefitinib 13Cyclophosphamide 13avelumab 12atezolizumab 12durvalumab 11Albumin-Bound Paclitaxel 11cemiplimab 9Radiation 8Drug Therapy 8alectinib 7Injections 7Etoposide 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Non-Small-Cell Lung × Decitabine × Clear all
NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Terminated
252 enrolled 67 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT01628471 2015-09-23

MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Uman Pharma

Phase 1/2 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡